v3.26.1
Other disclosures (Tables)
12 Months Ended
Dec. 31, 2025
Remuneration  
Schedule of direct and indirect voting rights in subsidiaries and other investments

  ​ ​ ​

2025

Company’s

 voting 

rights

%

Subsidiaries

Aptuit Global LLC, Princeton, USA

 

100

Aptuit (Verona) SRL, Verona, Italy

 

100

Aptuit (Oxford) Ltd., Abingdon, UK

 

100

Cyprotex Discovery Ltd., Manchester, UK

 

100

Cyprotex Ltd., Manchester, UK

 

100

Cyprotex US, LLC., Framingham, USA

 

100

Evotec (France) SAS, Toulouse, France

 

100

Evotec ID (Lyon) SAS, Marcy l’Étoile, France

 

100

Evotec (Hamburg) GmbH, Hamburg, Germany

 

100

Evotec GT GmbH, Orth an der Donau, Austria*

 

100

Evotec (India) Private Limited, Thane, India*

 

100

Evotec International GmbH, Hamburg, Germany

 

100

Evotec (UK) Ltd., Abingdon, UK

 

100

Evotec (US), Inc., Princeton, USA

 

100

Just - Evotec Biologics, Inc., Seattle, USA

 

100

Evotec (Modena) Srl, Medolla, Italy

100

NephThera GmbH, Hamburg, Germany

100

Evotec Asia Pte. Ltd., Shenton, Singapore

100

  ​ ​ ​

2025

Company’s 

voting 

rights

%

Associates

 

  ​

Breakpoint Therapeutics GmbH, Hamburg, Germany

34.03

Centauri Therapeutics Ltd., Cheshire, UK

 

22.18

EIR Biotherapies S.r.l., Mirandola (MO), Italy

 

24.66

Eternygen GmbH, Berlin, Germany*

 

24.97

Quantro Therapeutics GmbH, Vienna, Austria

 

38.79

TAG Therapeutics GmbH, Vienna, Austria

 

20.16

Topas Therapeutics GmbH, Hamburg, Germany

 

23.86

Other Investments

 

Aeovian Pharmaceuticals Inc., San Francisco, USA

 

2.32

ArgoBio SAS, Paris, France

8.17

Aurobac Therapeutics SAS, Lyon, France

 

12.50

Autobahn Labs, LLC, Palo Alto, CA USA

 

10.53

Blacksmith Medicines Inc., San Diego, CA USA

 

17.97

Cajal Neuroscience Inc., Seattle, USA

 

1.18

Carma Fund I, Munich, Germany

 

10.00

Celmatix Inc., New York, USA

 

7.47

Curie Bio LLC, Boston, USA

 

0.10

Curie Bio Seed Fund I LP, Boston, USA

 

2.83

Extend S.r.l., Rome, Italy

9.10

Fibrocor LLP, Toronto, Canada

16.26

Fibrocor Therapeutics, Inc., Toronto, Canada

7.65

IMIDomics Inc., San Rafael, CA, USA

6.64

Immunitas Therapeutics Inc.*, Waltham, USA

5.54

Leon Nanodrugs GmbH, Munich, Germany

3.99

Mission BioCapital V LP, Cambridge, USA

3.64

Pluristyx Inc., Seattle, USA

 

3.79

Sernova Corp., Ontario, Canada

4.73

Thelior Bio, Oxford, UK

1.18

Tubulis GmbH, Munich, Germany

3.33

Verto Therapeutics Inc., Boston, USA

4.16

*

in liquidation

Management Board  
Remuneration  
Schedule of remuneration granted to the members of the Management Board and remuneration accrued for the members of the Supervisory Board

in k€

  ​ ​ ​

2025

  ​ ​ ​

2024

Short-term employee benefits

 

5,503

4,238

Termination benefits

1,506

1,360

Stock-based compensation

 

247

(2,231)

Total Remuneration

 

7,256

3,367

Supervisory Board  
Remuneration  
Schedule of remuneration granted to the members of the Management Board and remuneration accrued for the members of the Supervisory Board

in k€

  ​ ​ ​

2025

  ​ ​ ​

2024

Total remuneration of the supervisory board

 

670

641